BRIGHTON A major expansion at the Oxford Recovery Center promises to offer children with autismsafe and controlled experiences in "real-world" situations.

Officials with the organization sayThe Village of ORC at the Oxford Recovery Center, the first such center in the United States,isdesigned to bring therapy and hands-on experience together for those who struggle with person-to-person interactions.

Founder and CEOTami Peterson said the objective is to create real-world scenarios for children and young adults so they will know how to behave when confronted withsimilar circumstances in everyday life.

"We created the real world environment the best we could," Peterson said."Kids with autism deserve the best and we really do believe that and practice that."

Peterson saidchildren with autism don't interpret the difference between real and fakesituations well, so it'sdifficult for them to pretend.

The organization hosted agrand opening on Saturday, June 11at 7030 Whitmore Lake Road.The $12-million, 35,000-square-foot building took more than a year to complete.

"I'll get emotional. I was in awe to be able to move into this building. I literally never thought we would use it. God says he always makes things more immeasurably beyond our belief. I say I dream small, God dreams big," Peterson said. "He gave me the vision. I never believed that this was planned. I get to watch people get their lives back every day and God chose me to do this. Clearly he does not choose people who are equipped he equips those he chooses."

The Village of ORC includes 12 functioning "retail stores," as well as a park featuring a road, curbs, sidewalks, benches, street lamps, stoplights, cross walks and an indoor playscape.

The 12 storesincludea grocery store, smoothie station, toy jungle, village caf, coffee house, pet store, Dino Dentistry, gift shop, a Huntington Bank ATM andhair salon. All proceedsgo towardthe Oxford Kids Foundation.

The retail stores are open to the public, and operated by people fromthe Creating Opportunities Maximizing Potential Achieving Successful Skillsprogram. According to Peterson, COMPASSis a six-month programfor young adults who have a degree or a diploma, are diagnosed with autismand are seeking employment.

Those adults enterthe program because theyare having trouble keeping jobsbecause of autism-associated behaviors. According to Peterson, only 8% of young adults with autism have meaningful employment. The COMPASS program allows individuals to self assess and work on goals.

"We can contrive scenarios in our different stores as they are spending time working in those stores," Peterson said.

Children in the Autism Recovery Through Synergy programparticipating in ABA therapy, such as speech, occupational and physical therapy, can work on their daily goals, too.

Goalsmay include such things asstanding in line at a grocery store,learning how to order their own food or getting their teeth cleaned at the dentist.

The stores can be used to practice executive functioning skills, intrapersonal skills and the opportunity to problem solve real world scenarios, according to Peterson.

Thepark provides a wayto teach children how to behavein a park, as well aswhat to do on a sidewalk or in a cross walk.

Other aspects of the expansion include a commercial kitchen where a trained chef will prepare lunches, multipletreatment rooms,a water room, and an art and music room.

The water room can help clients become desensitized to common sensory aversions like getting their hair or face wet. It can also simulate a thunderstorm to get clients comfortable with the sounds that come from storms.

In addition to treatment for autism-related issues, ORC offers physical, occupational and speech therapy, as well as, hyperbaric oxygen therapy, neurofeedback therapy and medical lab testing. They provide treatment for issues related to cerebral palsy, traumatic brain injury, stroke, Parkinson's and other conditions.

Peterson founded the center in 2008 after her daughter, JeAnnah Powell, responded well tohyperbaric oxygen therapy after contracting viral encephalitis in 2006 when she was 9.

The center was first located in 1,800-square-foot space in South Lyon. Additionally, they have a locationin Troy. The ORClater expanded into a 24,000-square-foot facility in Brighton in 2018.

Xander Salsitz, who performed as a saxophonist at the grand opening, has been a client and said he's benefited from the center.

In January 2012, at 8 years old, Salsitz was diagnosed with myelodysplastic syndrome, afull deletion of chromosome 7 in the bone marrow stem cell, which quickly led to complete bone marrow failure.

After two failed transplants, his family stumbled onto the hyperbaric oxygen therapy in South Lyon.

"We're very grateful and I did (hyperbaric oxygen treatments)over 760 times, I probably wouldn't be standing here today if it wasn't for Tami," he said.

Salsitz is set to bea freshman at the University of Michigan in the fall, where he will seeka bachelor's degree in music theory, focusing on jazz and contemporary improvisation.

ContactLivingston Daily reporterPatricia Alvord at palvord@livingstondaily.com about news coverage.

Here is the original post:
Oxford Recovery Center in Brighton reveals $12M expansion - Daily Press & Argus

This is the time of the year when most of us head outdoors for some sunshine and fresh air but did you know a poisonous plant is spreading across Arkansas like wildfire that is so toxic if you come in contact it could land you in the hospital or even kill you.

The flowering plant is known as hemlock one of the most poisonous plants in the world, according to the United States Department of Agriculture and it has been seen growing all over the state. You may often see these white flower pedal flowers growing in your backyard, nearby wooded areas, or along a fence line but don't let these flowers deceive you they are very toxic to humans and pets. For example, you could be cutting some bushes or brush around the house, or field, even brush against it on a hike and that could lead to some very serious health complications such as heart arrhythmias and could even slow down your heart rate, according to medical experts.

Other symptoms include nausea, vomiting, convulsions, trembling, and in some cases muscle paralysis all of which could land you in the ER if not taken seriously. The alkaloids could trigger impulse transmission to your muscles leading to respiratory failure and killing you. It doesn't take long for the toxins to take effect, normally around 10 minutes or longer.

If you think you have come in contact with hemlock, call your doctor or medical professional immediately.

Poison hemlock belongs to the same plant family as carrots, parsnips, fennel, and dill. The plant can grow from 2-to 10 feet tall and the entire plant is poisonous.

Poison Hemlock also has a dark past as mentioned in this video.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Read more:
Poison Plant Spreading in Arkansas That Could Kill You - kkyr.com

From heart transplants to implantable devices, BHF-funded science has helped to develop innovations that once seems like science fiction. Heres a preview of what the future of medicine might bring next.

Around one in every 200 newborn babies has a heart problem that needs surgery or another procedure. Professor John Simpson and his team at Evelina London Childrens Hospital and Kings College London are using a BHF grant to work on a virtual reality technology to improve these procedures.

He explains: We look at detailed scan images of an individuals heart in order to decide what is the right procedure, at the right time, with the minimum risk.

In the last couple of decades, weve gone from 2D to 3D images. But youre still looking at them on a flat screen. Even 3D printed models of hearts are not perfect you have to break it to see the structures inside. Also, the 3D models show the heart at one moment in time. But the living heart is dynamic; it beats, and the valves open and close.

With his teams new technology, information from heart scans routinely taken in hospitals can be turned into a virtual, beating heart. With the headset on, and joystick in your hand, the virtual heart is right in front of you. You can zoom in and out, see it from every angle and look inside, says Dr Natasha Stephenson, Professor Simpsons fellow researcher.

In a previous study, surgeons used the technology to review operations that had already taken place. They found that, compared to traditional 3D imaging, it gave them a better understanding of the patients heart and would have helped them better plan the surgeries. Now the team are working towards testing this technology to plan real procedures, which they hope to do in the next two years.

This technology allows surgeons to understand what theyll actually face in the operation, says Professor Simpson. You can put a virtual device into the virtual heart and see which will be the best device. Or even share the imaging with companies that can make bespoke devices to fit the individuals heart. We hope this will mean better repairs, fewer complications, shorter hospital stays and better long-term outcomes.

These virtual reality images can also be used to show patients what the issues are with their heart, or used to train doctors.

While Professor Simpsons focus is on congenital heart diseases, he says, In the long term, this technology could also help better visualise the problems of adults with other types of heart disease.

Sign up to our fortnightly Heart Matters newsletter to receive healthy recipes, new activity ideas, and expert tips for managing your health. Joining is free and takes two minutes.

After a heart attack, some heart muscle cells can die off, which can lead to heart failure. Dr Nicola Smart is trying to answer questions that might one day help us to help hearts regrow themselves.

From studies in mice, we know a couple of days after birth, the heart can fully regenerate. A week after birth, it loses that ability, explains Dr Smart.

To repair itself, the heart needs to grow new blood vessels, as well as new muscle. In adults, there is some growth of blood vessels, but it happens slowly and inefficiently.

She and her team at the University of Oxford are studying how different types of cells in different parts of the heart send signals to each other, helping the heart to grow new blood vessels. Through a technique called single-cell RNA-sequencing, she is seeing which of the genes involved in this process are switched off (not expressed) in adults.

Single-cell RNA-sequencing has completely changed our level of understanding. It used to be that we could only look at overall gene expression changes in a heart. That could tell you nothing about how different cells were responding to a heart attack. Now we see which genes are being expressed in each cell, we know even the same types of cells will respond differently in different parts of the heart.

Dr Smart says were just at the start of understanding how this new knowledge might lead to treatments in future. Regrowing heart muscle and blood vessels is only one part. Other teams are looking at how to limit scarring and how to work with the immune system, which also influences the hearts ability to regenerate. But if we can bring together all these ideas, we could develop a combination therapy to stimulate the heart to regenerate, and that could prevent more people developing heart failure.

Scarring is part of the bodys healing process. But it can cause problems. After a heart attack, too much scarring can stop the heart working well and cause heart failure.

MRI scansare currently used to look at scars that have already formed in peoples hearts. Now BHF-funded research is developing a cutting-edge technique so doctors can track scarring as it happens.

Professor Marc Dweck and his team at the University of Edinburgh are using PET scanning, a type of very detailed scan that can show how your bodys cells are working. Were using a new tracer a special chemical, which attaches to cells that cause scarring. The tracer sends a signal that we can detect on the scan.

Right now, we dont have a clear idea of when scarring occurs following a heart attack. In people who develop heart failure, do they have too much scarring activity or is it that scarring doesnt turn off at the right time?

His team will try to find the answers by studying people whove recently had heart attacks, as well as people who have old scarring from previous heart attacks, and healthy people.

Understanding how scarring develops may help us predict who will make a good recovery after a heart attack and who will need more treatment to prevent heart failure, explains Professor Dweck. Were talking precision medicine: with better scanning, we can tailor the right treatment to the right patient.

Pulmonary arterial hypertension (PAH) is a rare but serious condition, which causes high blood pressure in the arteries of the lungs. It can lead to heart failure and can sometimes be fatal. Currently there is no cure. BHF-funded researcher Alex Ainscough, at Imperial College London, is developing a new way to look for treatments.

He's created a pulmonary artery on a chip, in which the innermost layers of the artery walls are recreated inside a silicone rubber microchip just 1mm wide (the same size as the small arteries that are first affected in PAH).

In traditional research, you look at one type of cell, but in our bodies different cell types interact with each other, explains Dr Ainscough. We are trying to make it as representative of the human body as possible.

By running liquid through the chip, he can mimic the flow of blood in the body, which has a big impact on the cells. He explains: When you grow cells in a petri dish for research, its like theyre in the calm of a lake; but in the body, they are being subjected to forces like a fast-flowing stream.

He created a model of a diseased artery by using stem cells from people with PAH to create a pulmonary artery on a chip, which led to him discovering a previously unknown way in which PAH develops.

As well as being used as an investigative tool to understand how PAH happens, the pulmonary artery on a chip is being used to try out potential treatments. Dr Ainscough is working with a pharmaceutical company to test some of their existing drugs, as well as new drugs that are in development to treat PAH.

He predicts that in future, organ-on-a-chip models will help make treatments cheaper and quicker to develop. These models more closely match conditions in people compared to traditional petri dish research, so it will be faster to identify promising drugs before moving to clinical trials.

Theres also potential to use these for more personalised medicine. You could use stem cells from a particular person to create a microchip model to see how theyll react to a specific drug before giving it to them.

Most babies having surgery for heart defects will need repairs using additional materials such as patches, valves or tubes. These products are either made from animal tissue or synthetic material: they wont grow with the child and will become scar tissue and gradually deteriorate.

Massimo Caputo, BHF Professor of Congenital Heart Surgery at the University of Bristol, explains: This means a child might need surgery weeks after theyre born, again after a year or two, then after another five years, and carry on having repeated surgeries all their lives.

Each surgery can cause more scarring, which can cause problems like heart failureor abnormal heart rhythms. Theres also the mental stress of going through these operations. For years, patients and parents have said to me, Why cant we have a valve that lasts forever?

Thanks to one of our research grants, Professor Caputo is developing a kind of living tissue, made partly from stem cells, that will grow with the child. Hes currently in the process of securing regulatory approval and the first tests in patients should start in two to three years.

This living tissue could reduce the need for multiple surgeries, in adults as well as children. If you have a valve replacement from animal tissue, this will wear down and you will need to replace it after 10 years. Even if youre in your 50s or 60s, that could mean multiple surgeries. The tissue Im working on could be applied to adult surgery too, says Professor Caputo.

Another benefit is that this tissue could be less likely to be rejected by the body: A patients own stem cells could be used to produce the tissue, so that the immune system recognises it and doesnt reject it.

Published 10 June 2022

Continued here:
From sci-fi to reality: a peek into the future of medicine - British Heart Foundation

Wildlife trafficking, which is the illegal trade of wild animals and plants, either as dead or live specimens, or their parts, has a huge negative effect on the worlds environments, biodiversity, economies, governance, and health. It is a form of transnational organised crime that spans across many countries and involves poaching, smuggling, and illegal collection or capture, of protected wildlife.

According to the World Wildlife Fund (WWF), wildlife trafficking is the fourth largest form of transnational organised crime (after smuggling of drugs, human trafficking, and counterfeiting) worth anestimated 15 billion per annum.

ADVERTISEMENT

CONTINUE READING BELOW

Despite being a part of theCITES(Convention on International Trade in Endangered Species of wild fauna and flora), India is currently one among thetop 20 countriesfor wildlife trafficking, and among thetop 10 for wildlife trafficking by air. Due to its megadiverse nature (India has 8% of the worlds wildlife), and dense human population (which makes tracing illegal goods very difficult once they have entered domestic markets), India serves as both, a source, as well as a transit country for illegal wildlife and wildlife products.

Added to this, several other factors have made the fight against the illegal wildlife trade increasingly difficult. Amongst these are the porous international borders with China, Myanmar, and other Southeast Asian countries, agrowing aviation marketand thefast-expanding airport sector, and theuse of social media as online marketplacesby wildlife traffickers.

Furthermore, smugglers of exotic wildlife species in India have even resorted tomisusing the Voluntary Disclosure Schemeissued by the Ministry of Environment, Forest and Climate Change (MoEFCC) in 2020. Theschemeaimed to regulate the growing market of exotic animals in India which boomed after the complete ban on trade in Indian species by allowing Indians to declare the possession of exotic wild species without any documentation before March 15, 2021.

Besides these reasons, there are majorlacunae in lawsthat pertain to the ownership of exotic animals in India. People caught transporting exotic wildlife species can be charged with the crime only if it can be proven that they crossed an international border illegally with those animals. Once inside India, there are no policies or laws that regulate the ownership of exotic species. The Wildlife Protection Law only applies to Indian wildlife, says Sanjeev Pednekar, founder of Prani,an education centre and pet sanctuaryfor rescued birds and animals in the outskirts of Bengaluru.

Since India is not only a major source, but also a transit, and destination country for trafficked wildlife and wildlife products, a large number of species are illegally transported out of and into the country. According to theSmuggling in India report 202021, the DRIs (Directorate of Revenue Intelligence) most common wildlife and wildlife products that were seized from being smuggled out of India are ivory, turtles and tortoises (especially the Indian star tortoise), and red sandalwood (red sanders orlalchandan). Lately, there has been a decline in rhino horn trading from India; however, the country is fast becoming a major hub forpangolin poaching and trafficking. The trade in tiger parts also seems to becontinuing unabated.

ADVERTISEMENT

CONTINUE READING BELOW

In addition, ornamental fish such as theChanna barca or snakehead(endemic to the upper Brahmaputra basin) and thezebra loach(in the Western Ghats) are being fished to extinction in their natural habitats to feed the international trade in live aquarium fish. Along with these, wildlife trafficking has expanded to include trade in body parts ofgolden jackals,Asiatic black bears,leopards(for tantric uses and traditional medicines) andmongooses(for mongoose hair paintbrushes).

According to the Trade Records Analysis of Flora and Fauna in Commerce (TRAFFIC)Runway to Extinction reportpublished in 2020, although the trafficking of Indian star tortoises out of India is declining, the smuggling of red eared slider turtles is on the rise. Instances of exotic animals such as kangaroos, marmosets, tamarins, and birds such as macaws and parrots being transported across India areon the rise. The latest in this string of reports rolled in during March and April 2022, with videos of dehydrated and sickkangaroos rescued in West Bengal.

Apart from the illegal import and export of wildlife and wildlife products, India also has a roaring domestic market for wildlife meat and body parts for traditional medicine, including those offreshwater turtles,lorises, andfrogs.

International wildlife trafficking into and out of India mainly occurs through two routes one, through the long international border along the Northeast, and the other, through airports. The 2018 TRAFFIC reportIn Plane Sightnotes that trafficking in rhino horns, tiger parts, and pangolin scales is especially rampant in the Indo-Nepal, and Indo-Myanmar-China borders, with Northeast Indian cities such as Dimapur, Guwahati and Imphal being used a transit sites. Trafficking of birds and reptiles along the India-Bangladesh border is also rampant. Most recently, the Dooars region in northern West Bengal, specifically, the town of Jalpaiguri, made news as an emerging transit point for trafficking of exotic animals and birds.

Thetrafficking of reptiles, specifically turtles and tortoises, into and out of India is especially rampant, with Chennai and Mumbai airports being major hubs for this activity. The Indian star tortoise, which is the most trafficked reptile in the world, is supplied from trade hubs in Karnataka,Andhra Pradesh, Gujarat, and Tamil Nadu, to Thailand, Singapore, and Malaysia, primarily by air. Seizure data from the website Reducing Opportunities for Unlawful Trade of Endangered Species (ROUTES) shows that more than 54% of the trafficked animals were inchecked-in luggageand about 11% inair cargo. The top Indian cities where such airport seizures happen include Chennai, Kolkata, Mumbai, and Delhi, with reptile seizures being especially high in Chennai airport.

ADVERTISEMENT

CONTINUE READING BELOW

Wildlife trafficking in India is driven by many factors. The foremost of these is the demand for raw material like red sandalwood and ivory (used in manufacturing luxury products), and animal parts particularly rhinoceros horn and tiger parts for traditional medicine. TheWorld Wildlife Crime Report 2020states that although global markets for rhino horn and ivory have fallen consistently since 2011, new market demands such as those for pangolin scales and European glass eels have emerged. In Assam, because ofintense hunting of pangolins by local tribes, which eat the meat and sell the scales, this once-abundant animal is now relatively rare. The traditional medicine markets in China and Vietnam are major consumers of pangolin scales, rhino horns, and the skin and body parts of various big cats, birds, Asiatic black bears, musk deer, wolves, and jackals.

Another factor that drives wildlife trafficking is the demand for meat many animals such as theBengal slow loris,softshell turtles from Uttar Pradesh, deer, antelope, wild cattle, and even sea cucumbers are mainly trafficked for consumption.

The third major driving factor for wildlife trafficking in India lies in thegrowing demand for exotic pets,especially birdslike cockatoos, macaws, and grey parrots. In addition many Indianbirds,fish, andreptilesare in great demand in global pet markets. What is even more shocking, is that zoos may also be involved in illegally buying exotic animals, as per a recent caseinvolving Indore zoo and its connection to kangaroosbeing transported from a farm in Mizoram.

The wildlife trade not only depletes environments of their natural inhabitants, but is also responsible foradded threats like the spread of invasive species and emergence of new zoonoses. The three factors in combination can leadto whole ecosystem collapsesand major disease outbreaks. Some of the most virulent viral diseases including Ebola, Marburg virus disease, SARS (Severe Acute Respiratory Syndrome), and the most recent pandemic COVID-19 (Coronavirus disease-19) have all arisen in areas where close human-wildlife contact occurred such as inwet markets.

Wildlife trafficking in India is rapidly wiping out populations of tigers, elephants, rhinos, pangolins, star tortoises, and many other native species. Simultaneously, invasive species like thered eared slider turtles(which are popular pets) andsuckermouth sailfin catfish(a common aquarium fish) are destroying natural habitats.

ADVERTISEMENT

CONTINUE READING BELOW

The DRI, which is in the forefront of thebattle against smuggling, has teamed up with the Indian Customs as a part of theGreen Customs initiativeof the World Customs Organisation, to counter wildlife trafficking into and out of India. To combat the rising use of air transport in wildlife trafficking,a suite of toolsto help law enforcement agencies in India battle wildlife smuggling have been developed by TRAFFIC, along with the United Nations Environment Programme (UNEP), World Wildlife Fund-India (WWF-India), and theWildlife Crime Control Bureau(WCCB).

Apart from this, the International Air Transport Association (IATA) also has ashort 20-minute training moduleto help spread awareness on wildlife trafficking through air transport. Airport authorities in Bengaluru have even set up aforest cellto tackle wildlife smuggling. TheCounter Wildlife Trafficking program, run by the Wildlife Conservation Society-India, conducts training and sensitisation workshops for state forest departments, police forces, customs officials, border security force units, and even the judiciary, on conducting crime scene investigations and promoting inter-agency collaborations.

In addition to all these initiatives, the WCCB hasbegun profiling criminalsin a real-time database and will soon network with neighbouring countries (Nepal, Bhutan, Bangladesh, and Myanmar) to stem transboundary wildlife crime.

Molecular biology tools, includingDNA testingand bioinformatics are also being used in wildlife forensics to identify thepoint of origin of trafficked animal products. In addition, citizen science initiatives,dog squads, and various DNAdatabasesandreference librariesare being used to monitor animal populations susceptible to poaching and the wildlife trade. India alsodestroys seized wildlife productsto send out a strong anti-poaching message.

However, despite these efforts wildlife trafficking in India is still rampant. Indias CITES membership as well asits strong laws(Wildlife Protection Act, 1972) prohibiting the trade of over 1,800 species of native plants, animals, and their products are ineffective in tackling wildlife trafficking as these laws/advisories are often poorly communicated and enforced. In addition, wildlife experts say that India needsstronger laws to deal with exotic speciesthat have been smuggled into the country, which is a huge lacuna that is exploited by smugglers to feed the exotic pet trade.

ADVERTISEMENT

CONTINUE READING BELOW

Most often, when exotic live animals that have been smuggled into India are seized, they are sent to rescue centres or sanctuaries. Since zoos are usually meant to showcase Indian native wildlife, they often do not have adequate quarantine centres or appropriate enclosures to properly manage seized exotic animals.

Sanjeevs sanctuary, Prani, currently houses many exotics iguanas, monitor lizards, red-eared sliders, and emus to name a few. Nearly 90% of the exotic birds that we have at Prani, along with our iguanas, were given up by people who could no longer care for them. Sometimes, we also rescue animals meant for slaughter, such as our emus, says Sanjeev. In addition, Prani also has also been working/volunteering with the airport authorities in Bengaluru, the Forest Department, and the Animal Welfare Board of India, who often hand over seized animals to us. One memorable instance that stands out in my mind was when we had to care for over a hundred tiny Hamilton turtles one of the most endangered species of turtles in the world that were seized at the Kempegowda International Airport, he adds.

Sanjeev ruefully admits that he often takes in red eared sliders out of fear that people will abandon them in local lakes and ponds, where these terrapins can destroy the ecosystem and kill off native species. Since theCITES rulesdo not usually allow for reintroduction of exotic species to their natural habitats (except under very stringent circumstances), humane euthanasia or a lifetime of captive care are the only ways to deal with smuggled exotics.

Since most people will not even entertain the idea of euthanasia, most exotics are usually condemned to life in captivity. And so many of the exotic species smuggled into India such as capuchins, marmosets, and wallabies, which fetch good sums when sold are returned to the pet market, while others, like the red eared sliders are either given up to rescue centres or subject to uncontrolled releases, he adds.

Also read: Heres why ADHD can make it harder to keep eating habits in check

ADVERTISEMENT

CONTINUE READING BELOW

Latest Stories

Read this article:
Heres what makes India a major hub for wildlife trafficking - EastMojo

A couple of 'restaurant' shows have come to Loveland in the last year, and now it seems as though another one is here to do their thing.

It was in October of 2021, that 'Restaurant Impossible' came to Loveland to help out Casa Real. They did make improvements, though not everyone was keen on what they did.

It's fun when a television show comes to your hometown to film. I grew up in Loveland, and still get giddy when these stories come out. 'OOH! A TV star is coming to Loveland! Cool!' How many different cities/towns do these shows go to, all the time, and face 'yocals' like me? It must be in the hundreds.

Downtown Loveland's The Ball Joint was on The Cooking Channel's 'Food Paradise' in February of 2022, and really gave them a shot in the arm. Publicity, in the form of being on TV, does go a long way. The Ball Joint, however, was just showcasing their unique menu, they weren't getting advice or a renovation.

This new visit sounds like advice and a renovation.

It sounds like Jon Taffer and the gang at Bar Rescue are coming into to help out a long time eatery.I've eaten there, had drinks there, many times. It's a very friendly place with good food. CJ's Patio Grill.

I checked out there Facebook page when I got the lead, and they are indeed closing for a few days.

CJ's-Patio-Grill-Closed

I went over to CJ's on the morning of June 7, 2022. The parking lot had about a dozen parking spaces blocked off around the perimeter of the lot, and a some staffers were seated outside. A staffer saw me walking up to take a photo; we had a discussion:

We're closed.

I heard that Bar Rescue is coming, is that true?

I can't say... Non-Disclosure Agreement...

Here we are with another 'NDA' for the Fort Collins area.Interesting, no? I hope that things aren't in terrible shape for CJ's; I've seen Bar Rescue, and when Jon comes to your place, he's going to get in somebody's face, probably yours.

In the end, it's going to be great to get in there and see that they changed. I have a few ideas on what they might do, design wise. Hopefully, everybody walks away happy, with little tears shed.

CJ's-Patio-Grill-Loveland

As Loveland looks at 2022, let's look at 22 things the city could use.

Some of these joints have been gone for decades; a few, not that long.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Go here to read the rest:
Has Another Restaurant Show Come to Loveland to Make People Cry? - Retro 102.5

ABSTRACTS 7518, 7509, 8009

Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.

CAR T cell therapy shows durable responses after three years for patients with mantle cell lymphoma (Abstract 7518)Three-year follow-up data from the Phase II ZUMA-2 trial showed a long-term survival benefit and low disease relapse potential with one infusion of the anti-CD19 chimeric antigen receptor (CAR) T cell therapy brexucabtagene autoleucel (KTE-X19) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Principal investigator Michael Wang, M.D., professor of Lymphoma and Myeloma, presented results from the trial, and study results were published in the Journal of Clinical Oncology.

The updated results include all 68 patients treated with KTE-X19 on the trial with an additional two years of follow-up. After 35.6 months median follow-up, the overall response rate was 91%, with a 68% complete response rate. The median duration of response was 28.2 months, with 25 of 68 treated patients still in ongoing response at data cutoff.

This represents the longest follow-up of CAR T cell therapy in patients with mantle cell lymphoma to date, Wang said. It is encouraging to see this therapy induced durable long-term responses and a low relapse rate for these patients.

All patients had R/R disease after receiving up to five therapies, and all had received previous Brutons tyrosine kinase (BTK) inhibitor therapy. BTK inhibitors have greatly improved outcomes in R/R MCL, yet patients who have subsequent disease progression are likely to have poor outcomes, with median overall survival of just six to 10 months. Few patients in this category qualify to proceed to an allogeneic stem cell transplant.

Response and survival benefits were positive regardless of the prior BTK inhibitor type. Ongoing effectiveness trended lower in patients with prior acalabrutinib exposure. More investigation is needed to determine the mechanism behind these differences. The findings support future study of CD19-directed CAR T cell therapy in patients with high-risk MCL in earlier treatment lines.

The researchers also evaluated minimal residual disease (MRD) as an exploratory endpoint using next-generation sequencing on 29 patients. Of those, 24 were MRD-negative at one month, and 15 of 19 with available data were MRD-negative at six months. Circulating tumor DNA analysis of MRD at three and six months was predictive of disease relapse.

The treatment was well tolerated, as reported in previous studies with this therapy. Only 3% of treatment-emergent adverse events (AE) of interest occurred since the primary report. The most frequent Grade 3 AE was neutropenia.

The study was funded by Kite Pharma, a Gilead Company. Wang has received research support and has served on the advisory board and as a consultant for Kite Pharma. A complete list of collaborating authors can be found within the abstract here.

Allogeneic gamma delta CAR T cell therapy displayed encouraging efficacy in B-cell lymphoma (Abstract 7509)In the Phase 1 GLEAN trial of ADI-001, an anti-CD20 CAR-engineered allogeneic gamma delta T cell product, the treatment was well tolerated and showed continued efficacy in patients with R/R aggressive B-cell lymphoma. Results from the ongoing trial were presented by Sattva Neelapu, M.D., professor ofLymphoma and Myeloma.

The first-in-human trial enrolled ten patients and eight were evaluable and monitored for at least 28 days. The median age was 62 years and patients received a median of 4 prior therapies. At Day 28, the overall response rate (ORR) and complete response (CR) rate based upon PET/CT was 75%. The ORR and CR rate was 80% at dose levels two and three combined. The ORR and CR rate in CAR-T relapsed patients was 100%.

The responses to ADI-001 in this population of heavily pre-treated and refractory lymphoma patients, including in those with prior CD19 CAR T cell therapy, is very promising, Neelapu said. These results suggest the potential for off-the-shelf gamma delta CAR T cell therapy to be an effective treatment possibility for patients with B-cell lymphoma.

While autologous CD19-targeted CAR T cell therapy has been effective in R/R large B-cell lymphoma, there remains a need for alternative cell-based therapies. This study uses a subset of T cells, known as gamma delta 1 T cells, isolated from the peripheral blood of donors as the basis for CAR T cell therapy.

Gamma delta 1 T cells are desirable because they are able to combine both innate and adaptive mechanisms to recognize and kill malignant cells, and high levels of these cells in hematologic and solid tumors are associated with improved clinical outcomes. ADI-001 expresses major histocompatibility complex (MHC)-independent gamma delta T cell receptors, therefore lowering the risk of graft versus host disease (GvHD) without the need for gene editing.

The median age on the study was 62 years, and patients had received a median of 4 prior therapies. The treatment was well tolerated with most related events being grade 1 or 2. There were two cases of cytokine release syndrome and one case of immune effector cell-associated neurotoxicity syndrome. There were no reported cases of GvHD or dose-limiting toxicity.

Enrollment in the trial is ongoing and a potentially pivotal program is planned.

The study was funded by Adicet Bio, Inc. Neelapu has received research support and has served on the advisory board and as a consultant for Adicet Bio and has intellectual property related to cell therapy. A complete list of collaborating authors can be found within the abstract here.

Expanded NK cells combined with chemoimmunotherapy achieved durable responses in multiple myeloma (Abstract 8009)Results from the expansion phase of a Phase II clinical trial demonstrated that umbilical cord blood-derived expanded natural killer (NK) cells combined with chemotherapy and immunotherapies achieved durable responses in patients with multiple myeloma. Results from the completed clinical trial were presented by Samer Srour M.D., assistant professor of Stem Cell Transplantation & Cellular Therapy.

Thirty patients on the trial received NK cells plus elotuzumab (an immunotherapy monoclonal antibody), lenalidomide (an immunomodulatory drug) and high-dose melphalan chemotherapy before autologous stem cell transplant (ASCT).

At three months post-transplant, 97% of patients achieved at least a very good partial response (VGPR), including 76% with a complete response or stringent complete response, while 75% were minimal residual disease (MRD)-negative. At a median follow-up of 26 months, only four patients had progressed. At two years, the progression-free survival rate was 83% and the overall survival rate was 97%.

Patients with high-risk multiple myeloma have more options to treat their disease than previous years, but they continue to have poor outcomes, Srour said. These results indicate excellent hematologic and minimal residual disease responses and improved survival for these patients, suggesting this approach could provide an additional treatment opportunity.

NK cells are white blood cells that monitor the body for virus-infected and cancerous cells. MD Anderson researchers pioneered the approach to isolate and expand NK cells from umbilical cord blood to be used as cellular therapies. Lenalidomide enhances NK cell function and antibody-mediated cell toxicity against tumor targets. Preclinical data showed that lab-expanded NK cells demonstrated higher elotuzumab-mediated cytotoxicity against myeloma targets than non-expanded cells, and that the addition of elotuzumab to lenalidomide amplified the cord blood-NK cell antibody-dependent cellular cytotoxicity against a commonly used cell line to evaluate novel therapies for multiple myeloma (MM1.S) targets.

The study enrolled 30 patients with high-risk multiple myeloma, with a median age of 63. Twenty-nine patients (97%) had Revised Multiple Myeloma International Staging System (R-ISS) stages 2/3, 40% had 2 high-risk genetic abnormalities, and 23% had deletions or mutations of TP53. The primary endpoints were best response rate (VGPR) and MRD three months after ASCT.

Before the ASCT, stem cells are taken from the patient and stored. After treatment with the immunotherapy and chemotherapy drugs, stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

The treatment was well tolerated, with no unexpected serious adverse effects attributable to NK cells noted. The investigators plan to launch a randomized clinical trial to further explore this treatment combination for patients with high-risk multiple myeloma.

This study was supported with funding from the High-Risk Multiple Myeloma Moon Shot, part of MD Andersons Moon Shots Program, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients lives. The research also was supported by Celgene, a Bristol Myers Squibb company.

Srour has no conflicts of interest. A complete list of collaborating authors can be found within the abstract here.

Original post:
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting - EurekAlert

Lenrt, S. et al. Trop2: Jack of all trades, master of none. Cancers 12, 3328 (2020).

PubMed Central Google Scholar

Remk, J. et al. Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition. Carcinogenesis 39, 14111418 (2018).

PubMed Google Scholar

Linnenbach, A. J. et al. Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proc. Natl. Acad. Sci. U.S.A. 86, 2731 (1989).

ADS CAS PubMed PubMed Central Google Scholar

Linnenbach, A. J. et al. Retroposition in a family of carcinoma-associated antigen genes. Mol. Cell. Biol. 13, 15071515 (1993).

CAS PubMed PubMed Central Google Scholar

El Sewedy, T., Fornaro, M. & Alberti, S. Cloning of the murine TROP2 gene: Conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int. J. Cancer 75, 324330 (1998).

PubMed Google Scholar

Lipinski, M., Parks, D. R., Rouse, R. V. & Herzenberg, L. A. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 78, 51475150 (1981).

ADS CAS PubMed PubMed Central Google Scholar

Stepan, L. P. et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues. J. Histochem. Cytochem. 59, 701710 (2011).

CAS PubMed PubMed Central Google Scholar

Trerotola, M. et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32, 222233 (2013).

CAS PubMed Google Scholar

Sozo, F., Wallace, M. J., Zahra, V. A., Filby, C. E. & Hooper, S. B. Gene expression profiling during increased fetal lung expansion identifies genes likely to regulate development of the distal airways. Physiol. Genomics 24, 105113 (2006).

CAS PubMed Google Scholar

McDougall, A. R. A. et al. The oncogene Trop2 regulates fetal lung cell proliferation. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, 478489 (2011).

Google Scholar

Mustata, R. C. et al. Identification of Lgr5-independent spheroid-generating progenitors of the mouse fetal intestinal epithelium. Cell Rep. 5, 421432 (2013).

CAS PubMed Google Scholar

Fernandez Vallone, V. et al. Trop2 marks transient gastric fetal epithelium and adult regenerating cells after epithelial damage. Dev. Camb. Engl. 143, 14521463 (2016).

Google Scholar

Sun, W., Wilhelmina Aalders, T. & Oosterwijk, E. Identification of potential bladder progenitor cells in the trigone. Dev. Biol. 393, 8492 (2014).

CAS PubMed Google Scholar

Tsukahara, Y., Tanaka, M. & Miyajima, A. TROP2 expressed in the trunk of the ureteric duct regulates branching morphogenesis during kidney development. PLoS ONE 6, e28607 (2011).

ADS CAS PubMed PubMed Central Google Scholar

McDougall, A. R. A. et al. Intrauterine growth restriction alters the postnatal development of the rat cerebellum. Dev. Neurosci. 39, 215227 (2017).

CAS PubMed Google Scholar

Tsujikawa, M. et al. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat. Genet. 21, 420423 (1999).

CAS PubMed Google Scholar

Takaoka, M., Nakamura, T., Ban, Y. & Kinoshita, S. Phenotypic investigation of cell junction-related proteins in gelatinous drop-like corneal dystrophy. Investig. Ophthalmol. Vis. Sci. 48, 10951101 (2007).

Google Scholar

Aizarani, N. et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature 572, 199204 (2019).

CAS PubMed PubMed Central Google Scholar

Goldstein, A. S. et al. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc. Natl. Acad. Sci. U.S.A. 105, 2088220887 (2008).

ADS CAS PubMed PubMed Central Google Scholar

Okabe, M. et al. Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development 136, 19511960 (2009).

CAS PubMed Google Scholar

Yang, J. et al. Trop2 regulates the proliferation and differentiation of murine compact-bone derived MSCs. Int. J. Oncol. 43, 859867 (2013).

CAS PubMed Google Scholar

Memarzadeh, S. et al. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc. Natl. Acad. Sci. U.S.A. 107, 1729817303 (2010).

ADS CAS PubMed PubMed Central Google Scholar

Li, T. et al. Trop2 guarantees cardioprotective effects of cortical bone-derived stem cells on myocardial ischemia/reperfusion injury. Cell Transplant. 27, 12561268 (2018).

PubMed PubMed Central Google Scholar

Wang, J. et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol. Cancer Res. 9, 16861695 (2011).

CAS PubMed PubMed Central Google Scholar

Dreyfuss, D. & Ricard, J.-D. Acute lung injury and bacterial infection. Clin. Chest Med. 26, 105112 (2005).

PubMed Google Scholar

GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 19802017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond. Engl. 392, 17361788 (2018).

Google Scholar

Osuka, A., Ogura, H., Ueyama, M., Shimazu, T. & Lederer, J. A. Immune response to traumatic injury: Harmony and discordance of immune system homeostasis. Acute Med. Surg. 1, 6369 (2014).

PubMed PubMed Central Google Scholar

Stoecklein, V. M., Osuka, A. & Lederer, J. A. Trauma equals dangerdamage control by the immune system. J. Leukoc. Biol. 92, 539551 (2012).

CAS PubMed PubMed Central Google Scholar

Huber-Lang, M., Lambris, J. D. & Ward, P. A. Innate immune responses to trauma. Nat. Immunol. 19, 327341 (2018).

CAS PubMed PubMed Central Google Scholar

Vieira Braga, F. A. et al. A cellular census of human lungs identifies novel cell states in health and in asthma. Nat. Med. 25, 11531163 (2019).

CAS PubMed Google Scholar

Travaglini, K. J. et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature 587, 619625 (2020).

ADS CAS PubMed PubMed Central Google Scholar

Yu, Y. et al. A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages. Nat. Commun. 5, 3230 (2014).

ADS PubMed Google Scholar

Angelidis, I. et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat. Commun. 10, 963 (2019).

ADS PubMed PubMed Central Google Scholar

Kim, E. Y. et al. Persistent activation of an innate immune axis translates respiratory viral infection into chronic lung disease. Nat. Med. 14, 633640 (2008).

CAS PubMed PubMed Central Google Scholar

Liu, Q. et al. Increased expression of TROP2 in airway basal cells potentially contributes to airway remodeling in chronic obstructive pulmonary disease. Respir. Res. 17, 159 (2016).

PubMed PubMed Central Google Scholar

Major, J. et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369, 712717 (2020).

ADS CAS PubMed PubMed Central Google Scholar

Kamata, H. et al. Epithelial cell-derived secreted and transmembrane 1A signals to activated neutrophils during Pneumococcal pneumonia. Am. J. Respir. Cell Mol. Biol. 55, 407418 (2016).

CAS PubMed PubMed Central Google Scholar

Katsura, H. et al. Human lung stem cell-based alveolospheres provide insights into SARS-CoV-2-mediated interferon responses and pneumocyte dysfunction. Cell Stem Cell 27, 890-904.e8 (2020).

CAS PubMed PubMed Central Google Scholar

Gerlach, R. L., Camp, J. V., Chu, Y.-K. & Jonsson, C. B. Early host responses of seasonal and pandemic influenza A viruses in primary well-differentiated human lung epithelial cells. PLoS ONE 8, e78912 (2013).

ADS PubMed PubMed Central Google Scholar

Shen, B. Q., Finkbeiner, W. E., Wine, J. J., Mrsny, R. J. & Widdicombe, J. H. Calu-3: A human airway epithelial cell line that shows cAMP-dependent Cl-secretion. Am. J. Physiol. 266, L493-501 (1994).

CAS PubMed Google Scholar

Rezaee, F. & Georas, S. N. Breaking barriers. New insights into airway epithelial barrier function in health and disease. Am. J. Respir. Cell Mol. Biol. 50, 857869 (2014).

PubMed PubMed Central Google Scholar

Soong, G., Parker, D., Magargee, M. & Prince, A. S. The type III toxins of Pseudomonas aeruginosa disrupt epithelial barrier function. J. Bacteriol. 190, 28142821 (2008).

CAS PubMed Google Scholar

Short, K. R. et al. Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions. Eur. Respir. J. 47, 954966 (2016).

CAS PubMed Google Scholar

Linfield, D. T., Raduka, A., Aghapour, M. & Rezaee, F. Airway tight junctions as targets of viral infections. Tissue Barriers 9, 1883965 (2021).

PubMed PubMed Central Google Scholar

Nakatsukasa, M. et al. Tumor-associated calcium signal transducer 2 is required for the proper subcellular localization of claudin 1 and 7: Implications in the pathogenesis of gelatinous drop-like corneal dystrophy. Am. J. Pathol. 177, 13441355 (2010).

CAS PubMed PubMed Central Google Scholar

Xu, P. et al. A new in vitro model of GDLD by knocking out TACSTD2 and its paralogous gene EpCAM in human corneal epithelial cells. Transl. Vis. Sci. Technol. 7, 30 (2018).

CAS PubMed PubMed Central Google Scholar

Nakato, G. et al. Amelioration of congenital tufting enteropathy in EpCAM (TROP1)-deficient mice via heterotopic expression of TROP2 in Intestinal EPITHELIAL cells. Cells 9, 1847 (2020).

CAS PubMed Central Google Scholar

Singh, R. et al. A new triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Mol. Cancer Ther. 15, 13111320 (2016).

CAS PubMed Google Scholar

Szala, S. et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc. Natl. Acad. Sci. 87, 35423546 (1990).

ADS CAS PubMed PubMed Central Google Scholar

Mashhadi, S. M. Y. et al. Shedding light on the EpCAM: An overview. J. Cell. Physiol. 234, 1256912580 (2019).

Google Scholar

Here is the original post:
TACSTD2 upregulation is an early reaction to lung infection | Scientific Reports - Nature.com

The bouncing orange specks could be popcorn dancing on a hot plate. But theres something odd about how they move. Individual kernels spin in tight circles. Pairs slow dance a pas de deux. A cluster performs one full rotation counter-clockwise before dispersing. Each collision sets off a new motion. They seem to bebehaving.

What look like popcorn kernels inthis short videoare in fact a swarm of microscopic xenobots: tiny living robots, assembled from frog cells.

While living robots might seem a strange concept, in fact the first robots were made of flesh, not metal. Theword was coined in 1921, in a play by Czech playwright Karel apek.Rossums Universal Robotswas a thought experiment along the lines of Mary Shelleys Frankenstein, about a scientists desire to create artificial people. Nature has found only one method of organising living matter, declares Rossum, the scientist in question. There is, however, another method, more simple, flexible and rapid which has not yet occurred to nature at all.

Imagine him sitting over a test tube and thinking how the whole tree of life would grow from him, says another character.

In the century that followed, however, robots developed as things of steel and wire, rather than living tissue. Engineering moved faster than biology, says Douglas Blackiston, a developmental biologist at Tufts University. But biology is rapidly catching up. Blackiston is one of a team of scientists designing xenobots: tiny living robots, painstakingly constructed from tissue harvested fromXenopus laevis, the African clawed frog.

Thefirst xenobotswere revealed to the world at the start of 2020: minuscule cubes formed of skin cells and propelled by two stubby legs made of heart muscle. They were designed by a computer algorithm and hand-built by researchers with the objective to make the xenobots walk. (In a pleasing coincidenceXenopus means strange foot.) These organic automatons could also work together to move particles around their environment, and unlike mechanical robots they self-healed when injured.

Read more here:
'Unnatural selection': How humans are altering the evolution of other animals - Genetic Literacy Project

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia- obe-cel: poster presentation in r/r primary CNS lymphoma- obe-cel: poster presentation in r/r B-non-Hodgkins lymphoma and chronic lymphoblastic leukemia- Conference call to be held on June 13, 2022 at 7:30 am EST/12:30 pm BST

LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of four abstracts submitted to the European Hematology Association (EHA) Congress to be held June 9-12, 2022. Autolus plans to present more detail on these programs and the next steps in a conference call following the EHA presentations, on June 13, 2022, details below.

We are delighted to be presenting encouraging early clinical data from four of our pipeline programs, including important additive safety and efficacy data from our lead asset obe-cel in indications beyond adult r/r B-ALL. These data demonstrate the inherent value in both our pipeline and our technology base from which it originates, said Dr. Christian Itin, Chief Executive Officer of Autolus. With oral presentations on the early safety, tolerability, feasibility and preliminary efficacy of AUTO4 and AUTO1/22, were in a great place to evaluate the next strategic steps for these candidates and further build on the data presented here.

Abstracts to be presented:

Conference Call

Management will host a conference call and webcast on June 13, 2022 at7:30 am ET/12:30 pm BST to discuss the EHA data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus website.

The call may also be accessed by dialing (866) 679-5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID: 6594553. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID: 6594553.

About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit http://www.autolus.com.

About obe-cel(AUTO1)Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with Autolus academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL. Autolus has progressed obe-cel to the FELIX trial, a potential pivotal trial for adult ALL.

About obe-cel FELIX clinical trialAutolus Phase 1b/2 clinical trial of obe-cel is enrolling adult patients with relapsed / refractory B-precursor ALL. The trial had a Phase 1b component prior to proceeding to the single arm, Phase 2 clinical trial. The primary endpoint is overall response rate, and the secondary endpoints include duration of response, MRD negative CR rate and safety. The trial is designed to enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States,United KingdomandEurope. [NCT04404660]

About AUTO1/22AUTO1/22 is a novel dual targeting CAR T cell based therapy candidate based on obe-cel. It is designed to combine the enhanced safety, robust expansion & persistence seen with the fast off rate CD19 CAR from obe-cel with a high sensitivity CD22 CAR to reduce antigen negative relapses. This product candidate is currently in a Phase 1 clinical trial called CARPALL for patients with r/r pediatric ALL. [NCT02443831]

About AUTO4AUTO4 is a programmed T cell product candidate in clinical development for T cell lymphoma, a setting where there are currently no approved programmed T cell therapies. AUTO4 is specifically designed to target TRBC1 derived cancers, which account for approximately 40% of T cell lymphomas, and is a complement to the AUTO5 T cell product candidate, which is in pre-clinical development. AUTO4 has been tested in a Phase 1 clinical trial, LibRA1 for patients with peripheral T cell Lymphoma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus development of the obe-cel program; the future clinical development, efficacy, safety and therapeutic potential of its product candidates, including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and milestones; expectations regarding the initiation, design and reporting of data from clinical trials; expectations regarding regulatory approval process for any product candidates; the collaboration between Autolus and Blackstone; the discovery, development and potential commercialization of potential product candidates including obe-cel using Autolus technology and under the collaboration agreement; the therapeutic potential for Autolus in next generation product developments of obe-cel in B-cell malignancies; the potential and timing to receive milestone payments and pay royalties under the strategic collaboration; and the Companys anticipated cash runway. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Olivia Manser+44 (0) 7780 471568o.manser@autolus.com

Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com

Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com

More:
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress - GlobeNewswire

Saahil Joshi, age 17, Crystal Springs Uplands School, Hillsborough, Calif.: Too Many Cooks Spoil the Broth: The Science and Future of Drug-Drug Interactions

Micah: Salt: The Sapid and Sophisticated Seasoning

Katherine Kricorian, age 17, Santa Susana High School, Simi Valley, Calif.: From Algae to Energy: A Blooming Solution to Pollution

Chloe Lee, age 14, Korea International School Pangyo Campus, Gyeonggi-do, Korea: Do Plants Have Feelings?

Seungjae (Andy) Lee, age 13, Hong Kong International School, Tai Tam, Hong Kong: Keeping Your Pet Friend Forever: Is Cloning a Soul Possible?

Zhuocheng Li, age 16, Green Hope High School, Cary, N.C.: The Blood That Saved Countless Lives

Andrew C. Lin, age 12, Visions in Education Homeschool Academy, Carmichael, Calif.: Breaking the Speech Barrier

Andy Lu, age 16, Desert Vista High School, Phoenix: Hypersonic Flight: Can We Go Faster?

Camille: Sugar and the Body: A Bittersweet Relationship

Natalia Meza, age 17, American School of Madrid, Madrid: What Happens in Vagus, Stays in Vagus?

Aman Mistry, age 17, Smithtown High School, East Saint James, N.Y.: Helping a Blind Man See: The Miracle of Optogenetics

See the rest here:
Lasers, Fish-Skin Bandages and Pain-Free Vaccines: The Winners of Our 3rd Annual STEM Writing Contest - The New York Times